NZ720887A - Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide - Google Patents

Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide

Info

Publication number
NZ720887A
NZ720887A NZ720887A NZ72088714A NZ720887A NZ 720887 A NZ720887 A NZ 720887A NZ 720887 A NZ720887 A NZ 720887A NZ 72088714 A NZ72088714 A NZ 72088714A NZ 720887 A NZ720887 A NZ 720887A
Authority
NZ
New Zealand
Prior art keywords
crystalline forms
hcv
macrocyclic hcv
tripeptide
inhibiting
Prior art date
Application number
NZ720887A
Other languages
English (en)
Inventor
Dustin Bringley
Peter Fung
Katie Keaton
Olga Lapina
Henry Morrison
Johann Chan
Dominika Pcion
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of NZ720887A publication Critical patent/NZ720887A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
NZ720887A 2013-12-23 2014-12-18 Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide NZ720887A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920427P 2013-12-23 2013-12-23
PCT/US2014/071310 WO2015100144A1 (en) 2013-12-23 2014-12-18 Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide

Publications (1)

Publication Number Publication Date
NZ720887A true NZ720887A (en) 2018-01-26

Family

ID=52282995

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ720887A NZ720887A (en) 2013-12-23 2014-12-18 Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide

Country Status (12)

Country Link
US (2) US9562058B2 (enExample)
EP (1) EP3087086B1 (enExample)
JP (2) JP6568541B2 (enExample)
AR (1) AR098958A1 (enExample)
AU (1) AU2014370124A1 (enExample)
CA (1) CA2934049A1 (enExample)
ES (1) ES2708993T3 (enExample)
NZ (1) NZ720887A (enExample)
PT (1) PT3087086T (enExample)
TW (1) TW201609752A (enExample)
UY (1) UY35918A (enExample)
WO (1) WO2015100144A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201906413T4 (tr) 2013-12-23 2019-05-21 Gilead Sciences Inc Bir makrosiklik hcv ns3 inhibe edici tripeptidin sentezi.
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
JOP20170127A1 (ar) 2016-06-02 2017-12-02 Gilead Pharmasset Llc صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
CN115417803B (zh) * 2022-08-30 2023-10-03 四川同晟生物医药有限公司 乌帕替尼中间体(3r,4s)-1-苄氧羰基-4-乙基吡咯烷-3-羧酸的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
SI2540350T1 (sl) * 2008-07-22 2015-01-30 Merck Sharp & Dohme Corp. Kombinacije makrocikliäśnih kinoksalinske spojine, ki je hcv ns3 proteazni inhibitor z drugimi hcv uäśinkovinami
BR112013006693B1 (pt) * 2010-09-21 2022-07-12 Enanta Pharmaceuticals, Inc Compostos inibidores da serino protease hcv derivada de prolina macrocíclica
WO2012040040A1 (en) * 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
DK2907816T3 (en) 2011-11-16 2018-09-24 Gilead Pharmasset Llc CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с

Also Published As

Publication number Publication date
JP6568541B2 (ja) 2019-08-28
JP2019089819A (ja) 2019-06-13
JP2017503016A (ja) 2017-01-26
UY35918A (es) 2015-05-29
US20150175625A1 (en) 2015-06-25
EP3087086B1 (en) 2018-11-07
US9862728B2 (en) 2018-01-09
AR098958A1 (es) 2016-06-22
US9562058B2 (en) 2017-02-07
AU2014370124A1 (en) 2016-06-23
US20170267694A1 (en) 2017-09-21
EP3087086A1 (en) 2016-11-02
ES2708993T3 (es) 2019-04-12
PT3087086T (pt) 2019-02-06
WO2015100144A1 (en) 2015-07-02
TW201609752A (zh) 2016-03-16
CA2934049A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
NZ720887A (en) Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
WO2013059530A3 (en) Peptidomimetic macrocycles
EP3040193A4 (en) Waterproof breathable membrane, waterproof breathable component provided with same, waterproof breathable structure, and waterproof sound-permeable membrane
EP2279227A4 (en) ANIONIC LATEX AS VEHICLE OF ACTIVE INGREDIENTS AND METHODS OF MAKING AND USING THE SAME
HK1205454A1 (en) Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2015057087A3 (en) Headgear
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
EP3073756A4 (en) Waterproof sound-transmitting film and waterproof sound-transmitting structure using same
HK1202549A1 (en) Donepezil pamoate, preparation method and its use
SG10201503011PA (en) MEMBRANE COMPRISING SELF-ASSEMBLED BLOCK COPOLYMER AND PROCESS FOR PRODUCING THE SAME BY HYBRID CASTING (IIb)
WO2018098282A3 (en) Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
MX2014003180A (es) Metodos para tratar vhc.
MX2015011770A (es) Inhibidores dipeptídicos y tripeptídicos de epoxi cetona proteasa.
HK1231493A1 (zh) 药学上相关的芳香族阳离子肽
MY165041A (en) Composition for improving brain function and method for improving brain function
NZ724133A (en) Tfpi inhibitors and methods of use
EA201000039A1 (ru) Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль
WO2014149784A3 (en) Method and apparatus for soft switching welding type power
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
WO2014145314A3 (en) Methods and compositions for gamma-glutamyl cycle modulation
WO2016007956A3 (en) Cyclic tetrapeptide stereoisomers
EP2039708A4 (en) CYCLOOLEFIN ADDITIVE COPOLYMER, PREPARATION METHOD AND COPOLYMER RECEIVED DELAYING FILM
WO2015100370A3 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof
EP3064501A4 (en) 2-methylsulphanyl-6-nitro-7-oxo-1, 2, 4-triazolo [5, 1-c][1, 2, 4]triazinide l-arginine dihydrate active toward west nile virus
USD771901S1 (en) Glove back

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed